1 Reason Every Investor Should Know About AbbVie (ABBV)

Core Insights - AbbVie's ability to extend patent-protected market exclusivity for its drugs is a positive indicator for new investors [1][3] - The company has delivered a total return of 494% over the past decade, largely due to its successful management of patent exclusivity for its lead drug, Humira [3] - AbbVie has a strong track record of increasing dividend payouts, with a 221.6% increase over the past ten years [1] Patent Exclusivity - Composition of matter patents typically provide 25 years of protection, allowing drugmakers over a decade of exclusivity after new drug development [4] - AbbVie utilized a range of additional patents to delay biosimilar competition for Humira in the U.S. until 2023 [4] New Drug Performance - AbbVie's new lead drug, Skyrizi, has seen sales increase by 69% year-over-year in the first half of 2025, reaching $7.8 billion [6] - Rinvoq, another drug launched in 2019, generated $3.7 billion in sales during the same period, contributing to an overall 8% increase in total first-half revenue despite a significant decline in Humira sales [6] Dividend Yield - AbbVie currently offers a dividend yield of 3.1%, and if the company can maintain exclusivity for Rinvoq and Skyrizi as it did for Humira, shareholder dividends may increase significantly in the coming decade [7]